Form 8-K REGENERON PHARMACEUTICAL For: Aug 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron Pharma (REGN) PT Raised to $385 at Cowen
August 2, 2018 3:51 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
